Caris Life Sciences shared finalized results for its multi-cancer early detection test Caris Detect from the Achieve I study, lifting shares on the release. The study enrolled 3,014 evaluable patients across high-risk screening, symptomatic presentation, or detection of a mass on imaging. Caris reported sensitivity by stage ranging from 56.8% in stage I to 67.7% in stage II, 79% in stage III, and 98.6% in stage IV. Asymptomatic specificity was 99.2%, with benign/high-risk specificity at 96%, and sensitivity varied by cancer type. The company emphasized its whole-genome sequencing approach and AI models trained on molecular profiling data comprising more than 50 billion molecular markers. Caris also reiterated a plan to launch Caris Detect in Q2 2026 and said it intends to add whole-transcriptome sequencing to improve performance. For the MCED market, the finalized dataset narrows performance uncertainty versus interim reporting and provides a clearer basis for payer, clinical, and workflow conversations.